Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
Titel:
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
Auteur:
Sternberg, C.N. Dumez, H. Van Poppel, H. Skoneczna, I. Sella, A. Daugaard, G. Gil, T. Graham, J. Carpentier, P. Calabro, F. Collette, L. Lacombe, D.